financetom
Business
financetom
/
Business
/
Ventas Insider Sold Shares Worth $487,848, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ventas Insider Sold Shares Worth $487,848, According to a Recent SEC Filing
Sep 11, 2024 11:07 PM

05:43 PM EDT, 09/11/2024 (MT Newswires) -- Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas ( VTR ), and President and CEO, Lillibridge Healthcare Services, on September 10, 2024, sold 7,500 shares in Ventas ( VTR ) for $487,848. Following the Form 4 filing with the SEC, Bulgarelli has control over a total of 89,295 shares of the company, with 89,295 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/740260/000074026024000216/xslF345X05/wk-form4_1726090691.xml

Price: 64.35, Change: -0.98, Percent Change: -1.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
enGene Receives RMAT Designation From US FDA for Bladder Cancer Therapy
enGene Receives RMAT Designation From US FDA for Bladder Cancer Therapy
Jun 25, 2025
08:33 AM EDT, 06/25/2025 (MT Newswires) -- enGene Holdings (ENGN) said Wednesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to the company's lead investigational therapy, detalimogene voraplasmid, for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. enGene said the designation is designed to expedite the development of promising...
Novagold Resources Fiscal Q2 Net Loss Widens; Shares Up 2.8% in U.S. Pre-market
Novagold Resources Fiscal Q2 Net Loss Widens; Shares Up 2.8% in U.S. Pre-market
Jun 25, 2025
08:31 AM EDT, 06/25/2025 (MT Newswires) -- Novagold Resources ( NG ) traded 2.8% higher at last look Wednesday in NYSE American pre-market trading as the company's comprehensive loss widened in its fiscal second quarter. The company reported a comprehensive loss of US$53.7 million, or a US$0.15 per share, for the three months ended May 31, compared with a loss...
NovaGold Resources Fiscal Q2 Net Loss Widens
NovaGold Resources Fiscal Q2 Net Loss Widens
Jun 25, 2025
08:33 AM EDT, 06/25/2025 (MT Newswires) -- NovaGold Resources ( NG ) reported a fiscal Q2 net loss Wednesday of $0.15 per diluted share, compared with a loss of $0.04 a year earlier. Two analysts polled by FactSet expected a loss of $0.05. The company said it has not realized revenue from its principal asset, a 6 0% stake in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved